<DOC>
	<DOCNO>NCT00053937</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Pirfenidone may slow growth prevent development plexiform neurofibroma . PURPOSE : Phase I trial study effectiveness pirfenidone treat young patient neurofibromatosis type 1 plexiform neurofibroma .</brief_summary>
	<brief_title>Pirfenidone Treating Young Patients With Neurofibromatosis Type 1 Plexiform Neurofibromas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose `` comparable dose '' pirfenidone pediatric patient neurofibromatosis type 1 inoperable , symptomatic plexiform neurofibroma . - Determine toxic effect drug patient . - Determine plasma pharmacokinetics drug patient . - Determine , preliminarily , drug could beneficial pediatric patient refractory solid tumor . - Assess quality life patient treated drug . OUTLINE : This open-label , multicenter , dose-escalation study . Patients receive oral pirfenidone three time daily day 1-28 . Courses repeat every 28 day 2 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos pirfenidone maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Quality life assess baseline , course 4 , every 6 course . PROJECTED ACCRUAL : A total 3-18 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neurofibromatosis type 1 ( NF1 ) AND Plexiform neurofibromas Neurofibromas grown along length nerve may involve multiple fascicle branch ( spinal neurofibroma involve 2 level connection level extend laterally along nerve ) Potential cause significant morbidity : Head neck lesion could compromise airway great vessel Brachial lumbar plexus lesion could cause nerve compression loss function Lesions could result major deformity ( e.g. , orbital lesion ) significant cosmetic problem Lesions extremity cause limb hypertrophy loss function Painful lesion Meets least 1 diagnostic criterion NF1 6 cafeaulait spot ( least 0.5 cm prepubertal patient least 1.5 cm postpubertal patient ) Freckling axilla groin Optic glioma 2 Lisch nodule Distinctive bony lesion ( dysplasia sphenoid bone dysplasia thin long bone cortex ) Firstdegree relative NF1 Measurable plexiform neurofibroma At least 3 cm 1 dimension Tumor resection feasible No history malignant peripheral nerve sheath tumor cancer No evidence active optic glioma require chemotherapy radiotherapy No malignant glioma PATIENT CHARACTERISTICS : Age 3 21 Performance status Karnofsky 50100 % ( 10 year age ) Lansky 50100 % ( 10 year ) Life expectancy Not specify Hematopoietic Absolute granulocyte count least 1,500/mm^3 Hemoglobin least 9.0 g/dL Platelet count least 150,000/mm^3 Hepatic Bilirubin normal SGPT great 2 time upper limit normal No clinically significant hepatic dysfunction would preclude study participation Renal Creatinine normal age OR Creatinine clearance least 70 mL/min Cardiovascular No clinically significant cardiac dysfunction would preclude study participation Pulmonary No clinically significant pulmonary dysfunction would preclude study participation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study Must able take pirfenidone orally No serious infection No clinically significant unrelated systemic illness organ dysfunction would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy At least 30 day since prior immunotherapy No concurrent immunotherapy No concurrent hematopoietic growth factor Chemotherapy At least 30 day since prior chemotherapy No concurrent chemotherapy direct tumor Endocrine therapy At least 30 day since prior hormonal therapy direct tumor No concurrent hormonal therapy direct tumor Radiotherapy At least 90 day since prior radiotherapy site plexiform neurofibroma No concurrent radiotherapy direct tumor Surgery Not specify Other Recovered prior therapy More 30 day since prior investigational agent No prior pirfenidone No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>plexiform neurofibroma</keyword>
	<keyword>neurofibromatosis type 1</keyword>
</DOC>